e-learning
resources
Virtual 2021
05.09.2021
News in treatment and diagnosis of idiopathic interstitial pneumonia
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study
L. Thong Wan Yin (Co. Cork, Ireland), B. Bowen (Co. Cork, Ireland), M. Henry (Co. Cork, Ireland)
Source:
Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Session:
News in treatment and diagnosis of idiopathic interstitial pneumonia
Session type:
E-poster
Number:
463
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Thong Wan Yin (Co. Cork, Ireland), B. Bowen (Co. Cork, Ireland), M. Henry (Co. Cork, Ireland). Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study. 463
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study
Source: ERJ Open Res, 6 (1) 00172-2019; 10.1183/23120541.00172-2019
Year: 2020
Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort
Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Nintedanib in Idiopathic Pulmonary Fibrosis: a single-centre real-life experience
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients
Source: International Congress 2016 – IPF clinical
Year: 2016
Comparison of Interferon gamma-1b (IFN-γ)and colcicine in the treatment of Idiopathic pulmonary fibrosis: preliminary results of a prospective, multicenter randomised study
Source: Eur Respir J 2002; 20: Suppl. 38, 599s
Year: 2002
Prevalence of cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study
Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias
Year: 2018
Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2003 - Interstitial lung diseases
Year: 2003
The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study
Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis
Year: 2011
Pirfenidone post-authorization safety registry (PASSPORT) update
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study
Source: Eur Respir Rev 2008; 17: 116-122
Year: 2008
Late Breaking Abstract - Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY
Source: International Congress 2017 – Lung fibrosis: basic science
Year: 2017
Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Europe.
Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis
Year: 2021
Home oxygen saturation monitoring and quality of life in patients with idiopathic pulmonary fibrosis: A prospective multicenter trial
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Source: International Congress 2016 – IPF treatment I
Year: 2016
Inhaled beclomethasone/formoterol in idiopathic pulmonary fibrosis: a randomised controlled exploratory study
Source: ERJ Open Res, 3 (4) 00100-2017; 10.1183/23120541.00100-2017
Year: 2017
Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study
Source: International Congress 2014 – ILDs 6
Year: 2014
Post-marketing surveillance of pirfenidone for idiopathic pulmonary fibrosis in Japan: Interim analysis of 973 patients
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept